Navigation Links
Kosan Announces Data Presentations at Upcoming AACR Annual Meeting

HAYWARD, Calif., April 10, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated announced data will be presented on the Company's clinical and preclinical pipeline, including its Hsp90 inhibitor, epothilone and nuclear export inhibitor programs, at the 2007 Annual Meeting of the American Association for Cancer Research (AACR), being held in Los Angeles, April 14-18, 2007.

Poster presentations on Kosan's programs are as follows. The location for all poster presentations is the Los Angeles Convention Center Exhibit Hall.


    Date   Abstract #   Title             Session          Poster  Poster #

                                                           Section

    4/15

    1:00-  1544         Tanespimycin:     Experimental     32      4

    5:00                 No effects on     and Molecular

                         QTC interval      Therapeutics 13

                         using two

                         formulations


    4/15

    1:00-  1568         Preclinical       Experimental     32      28

    5:00                 safety profile    and Molecular

                         of tanespimycin   Therapeutics 13

                         (KOS-5: 953) --

                         a heat shock

                         protein 90

                         (Hsp90)

                         inhibitor


    4/15

    1:00-  1438         KOS-1803: A new,  Experimental     27      19

    5:00                 rationally        and Molecular

                         designed          Therapeutics 8

                         epothilone

                         analog with an

                         improved

                         pharmacological

                         profile and

                         efficacy in

                         xenograft mouse

                         models


    4/18

    8:00-  5597         Anti-tumor        Experimental     29      2

    12:00                activity of       and Molecu
'"/>




Page: 1 2 3

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
9. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... - 2014 Summary Global Markets Direct,s, ... 2014, provides an overview of the Arbor Pharmaceuticals, ... report provides comprehensive information on the current therapeutic ... comparative analysis at various stages, therapeutics assessment by ...
(Date:9/30/2014)... According to the ... Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments (HPLC, ... (Immunology, Oncology) & by End User - ... provides a detailed overview of the major ... and strategies impacting the global glycomics enzymes, ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals International, ... today announced that the company,s Bridgewater, New ... the U.S. Food and Drug Administration (FDA) relating to ... with regards to Sculptra Aesthetic injectable, which was divested ... to the management of Valeant,s contract manufacturers (rather than ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
(Date:9/30/2014)... and radiotherapy at the same time could stop them ... published in Cancer Research * today (Wednesday). ... Manchester and funded by MedImmune, the global biologics research ... found that combining the two treatments helped the immune ... killed by the initial radiotherapy in mice with breast, ...
(Date:9/30/2014)... News) -- There,s no genetic evidence that high levels ... new study says. Some previous research had suggested ... against type 2 diabetes, raising the possibility of a ... disease. In this study, British researchers investigated the ... on genes that control blood levels of vitamin D. ...
(Date:9/30/2014)... Randy Dotinga HealthDay Reporter ... unemployment rates climb, women tend to put the brakes on ... out to be a permanent choice, new research suggests. ... not to have a child during tough economic times. But, ... women will remain childless into their 40s and beyond. ...
(Date:9/30/2014)... Health Day Reporter TUESDAY, Sept. ... are overweight or obese when diagnosed appear to face ... cancer, new research suggests. , , The finding didn,t ... the potential for developing other cancers associated with obesity. ... reported being overweight or obese prior to diagnosis had ...
(Date:9/30/2014)... [Brown University] Autism is no stranger to the ... African nation is access to clinical services, including reliable ... measure, for example, validated for use in Swahili, a ... study, however, researchers at Brown University and the University ... that they implemented at two sites in the country ...
Breaking Medicine News(10 mins):Health News:Immunotherapy could stop resistance to radiotherapy 2Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 3Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4
... CHICAGO, Aug. 21 Illinois U.S. Senate candidate Cheryle Jackson ... achieve the dual goals of containing costs and expanding access to ... , Jackson said that health care cooperatives are not ... national public plan that competes with the private insurance industry because ...
... ... Attract, Retain and Serve Health Insurance Consumers , ... Orlando, FL (Vocus) August 21, 2009 -- As the ... is making individual consumers become more involved in the health insurance decision-making process, as ...
... Angeles, London, New Delhi, Singapore and Washington DC (August 21, ... could benefit from a lighter touch but from a ... created a touchy-feely robot that detects tougher tumour tissue in ... human. The technique also minimises tissue damage. Surgeons have ...
... Brown adipose tissue (BAT) brown fat, which is found ... lead to new ways of preventing obesity. Studies have ... obesity. Therefore, promoting BAT function could prevent or reduce obesity ... Symonds, Professor of Developmental Physiology in the School of Clincal ...
... Aug. 21 President Obama,s Council of Advisors on Science and ... reform, energy and the environment -- and the President is listening. ... little about our healthcare system that does not concern us," said ... A primary care physician, he noted that less than 20 ...
... and good rapport with physician is key, , FRIDAY, ... acid reflux is one of the most common complaints ... appear to work best to ease patients, suffering. , ... -- formally called gastroesophageal reflux disease (GERD) -- typically ...
Cached Medicine News:Health News:U.S. Senate Candidate Cheryle Jackson: 'Public Option Critical to Real Health Care Reform' 2Health News:Connextions Cited in Leading Industry Analyst Firm's 'Hype Cycle for Healthcare Payers' 2Health News:Connextions Cited in Leading Industry Analyst Firm's 'Hype Cycle for Healthcare Payers' 3Health News:Connextions Cited in Leading Industry Analyst Firm's 'Hype Cycle for Healthcare Payers' 4Health News:Robot's gentle touch aids delicate cancer surgery 2Health News:Robot's gentle touch aids delicate cancer surgery 3Health News:Daylight could help control our weight 2Health News:PCAST Members Advise President on Future of Healthcare, Energy 2Health News:Right Match of Drug, Doctor Can Boost Reflux Outcomes 2Health News:Right Match of Drug, Doctor Can Boost Reflux Outcomes 3
... Screen Tests are available in 14 configurations ... Designed using Microgenics Antibody Technology, the SureStep™ ... of care immunoassay targeted to detect MDMA ... and MDEA but no cross-reactivity to any ...
... The InstaCheck® multi-drug test device ... and easily. Negative results can ... as 3 minutes; positive results ... simple, one-time urine sample application ...
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
... onsite test! QuickScreen™ multi-panel dip cards offer ... your choice of any conceivable combination of ... flexibility for your drug testing program. Just ... the built-in timer tells you when to ...
Medicine Products: